See full news release here For Immediate Release HALIFAX, February 11, 2019—Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce the availability of its new CRYOcheck Factor VIII Inhibitor Kit in Canada, the European Union, Australia, and New Zealand following market authorization by Health Canada and respective in-country regulatory authorities…

See original release here For Immediate Release HALIFAX, July 19, 2018—Precision BioLogic today unveiled data from a study using a new kit for a Modified Nijmegen-Bethesda Assay (MNBA) at the International Society on Thrombosis and Haemostasis’ Scientific and Standardization Committee (SSC) meeting in Dublin. Recognizing the need to standardize and improve Factor VIII (FVIII) inhibitor…

See original press release here Precision BioLogic Inc. Banks on Developing New Diagnostic Tools From: Atlantic Canada Opportunities Agency News release Government of Canada supports research project to advance medical technology for clinical coagulation tests May 11, 2018 – Dartmouth, NS – Atlantic Canada Opportunities Agency Helping Atlantic Canadian businesses succeed by fostering greater innovation through…

See original release New data highlights promising performance of a new kit for use in a modified Nijmegen-Bethesda Assay For Immediate Release: HALIFAX, March 13, 2018—Precision BioLogic, in collaboration with Roche and Genentech, a member of the Roche Group, unveiled data from the study of a new kit for a modified Nijmegen-Bethesda Assay (MNBA) at…

For Immediate Release HALIFAX, October 2, 2017—Precision BioLogic is pleased to recognize the tenth anniversary of the Fritsma Factor—Your Interactive Hemostasis Resource, an online educational service moderated by George Fritsma and proudly supported by Precision BioLogic. In 2006, Fritsma—a lab scientist, educator and author—began looking for a means to share knowledge, information and insight about…

2015 © Copyright - Bionova